News | January 06, 2026
PHARMEXCIL holds high-level talks with government to boost India’s pharma exports
India’s pharmaceutical sector stands at a pivotal inflection point
India’s pharmaceutical sector stands at a pivotal inflection point
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Subscribe To Our Newsletter & Stay Updated
